Pay in 4 interest-free payments of $6.35 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Contraindications: BPC-157 therapy is not appropriate for patients with active cancer, during pregnancy or breastfeeding, or for those on blood thinners (anticoagulants) without provider clearance
We are just waiting for the green light from the FDA. Across the country, compounding pharmacies like Houston-based ReviveRx and Fort Lauderdale-based Hallandale have sprung up or expanded, while private-equity-backed Revelation Pharma has been rolling up compounding pharmacies into a larger operation
It is often stacked with TB-500 in the Wolverine protocol, and for patients pursuing broader recovery goals it can be combined with a growth hormone peptide protocol
The FDA subsequently classified AOD-9604 within Category 2 of the bulk drug substance review process, and the compound was later withdrawn from that nomination in April 2026
US$ 27.45
US$ 21.57
US$ 24.57
US$ 25.10
US$ 29.46
US$ 27.28
